Blueprint MedTech program aims to accelerate patient access to groundbreaking, safe, and effective medical devices. The program will provide support to sufficiently develop and de-risk technologies to the point where additional investments are warranted from industry partners, investors, and government.

Cooperative agreement and SBIR Fast-Track award programs support small molecule drug discovery and development.  These programs are designed to maintain the grantees’ intellectual property while providing non-dilutive funding.

The BPN Biologics program focuses on the development of diverse biotherapeutic modalities – including but not limited to antibodies, peptides, proteins, oligonucleotides, gene and cell therapies, and other emerging modalities – for the treatment of nervous system disorders. The program supports investigator-led translational projects, from lead optimization to first-in-human trials and provides resources to bridge critical gaps.

The NIH Blueprint for Neuroscience Research Initiative on Interoception is a two-phase effort to advance understanding of how organisms sense, interpret, integrate, and regulate internal bodily signals. Advancing interoception research is pivotal for health promotion and disease prevention, as impaired interoceptive function underlies conditions such as obesity, diabetes, anxiety, depression, substance use disorders, Alzheimer’s, Parkinson’s, autism, chronic pain, PTSD, IBS, fibromyalgia, and cardiovascular diseases.